Cambridge, United Kingdom

Matthew Kraman

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Matthew Kraman: Innovator in Cancer Therapy

Introduction

Matthew Kraman is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of cancer therapy through his innovative work. With a total of 3 patents, Kraman has focused on developing specific binding members that target lymphocyte-activation gene 3 (LAG-3).

Latest Patents

Kraman's latest patents include advancements in LAG-3 binding members. These inventions relate to specific binding members that bind to LAG-3, which is crucial in cancer therapy. The specific binding members are designed to include a LAG-3 antigen-binding site, potentially located in two or more structural loops of a CH3 domain. This innovative approach aims to enhance the effectiveness of cancer treatments.

Career Highlights

Throughout his career, Matthew Kraman has worked with prominent companies in the biotechnology sector. Notable among these are F-star Therapeutics, Inc. and Invox Pharma Limited. His work in these organizations has allowed him to contribute to groundbreaking research and development in the field of cancer therapy.

Collaborations

Kraman has collaborated with several talented individuals in his field. Some of his notable coworkers include Mihriban Tuna and Francisca Wollerton Van Horck. These collaborations have further enriched his research and innovation efforts.

Conclusion

Matthew Kraman stands out as an influential inventor in the realm of cancer therapy. His innovative patents and collaborations reflect his commitment to advancing medical science. His work continues to pave the way for new therapeutic approaches in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…